Please ensure Javascript is enabled for purposes of website accessibility

Why Viela Bio Stock Is Skyrocketing Today

By Prosper Junior Bakiny - Updated Feb 1, 2021 at 12:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company entered into an agreement to be acquired.

What happened

Shares of Viela Bio (VIE) were soaring Monday morning after it was announced that the biopharmaceutical company will soon be acquired by Horizon Therapeutics (HZNP -3.29%). As of 11:27 a.m. EST, shares of Viela Bio were up by 52.5%.

So what

Horizon Therapeutics will acquire all the outstanding shares of Viela Bio for $53 per share in cash. The price of this transaction represents a significant premium over Viela's stock price as of the closing of Friday's trading, which was $34.68.

That explains why investors rapidly bid up Viela Bio's shares this morning. Tim Walbert, CEO of Horizon Therapeutics, said, "This acquisition represents a significant step forward in advancing our strategy -- to expand our pipeline in order to accelerate our growth over the long term."

Letter blocks spelling "M&A."

Image source: Getty Images.

Perhaps the most important asset Horizon will get as part of this acquisition is Uplizna, a medicine for a rare autoimmune condition called neuromyelitis optica spectrum disorder (NMOSD). Uplizna is the only drug approved by the Food and Drug Administration for NMOSD.

"We are pleased that Horizon recognizes the value of our robust R&D pipeline; our commercial medicine Uplizna, which is an important treatment option for patients with NMOSD; and our talented team," said Bing Yao, CEO of Viela Bio. Horizon will also inherit Viela Bio's pipeline, including potential treatments for rheumatoid arthritis and more.

Now what

The transaction between these two healthcare companies is structured as a two-step cash tender offer, whereby Horizon Therapeutics will acquire all the remaining shares of Viela Bio (those not tendered through the offer) through a merger, still at the price of the tender offer ($53 per share). The deal is expected to close by the end of the first quarter.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viela Bio, Inc. Stock Quote
Viela Bio, Inc.
Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
$87.38 (-3.29%) $-2.97

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.